Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer " ETNA (Evaluating Treatment With Neoadjuvant Abraxane)

NCT01822314 is registered in ClinicalTrials.gov with Fondazione Michelangelo as lead sponsor.

NCT NCT01822314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer " ETNA (Evaluating Treatment With Neoadjuvant Abraxane)
Lead sponsor
Fondazione Michelangelo
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2013
Completion date
March 31, 2023
Enrollment
632 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer